Caffeine
The neuroprotective effects of caffeine in neurodegenerative diseases.
Neuroprotection of the preterm brain.
Caffeine; the Forgotten Potential for Parkinson's Disease.
Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease.
The epidemiology of Parkinson's disease: risk factors and prevention.
A Review of the Role of Green Tea (Camellia sinensis) in Antiphotoaging, Stress Resistance, Neuroprotection, and Autophagy.
Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis.
Caffeine, creatine, GRIN2A and Parkinson's disease progression.
Protective Effects of the Caffeine Against Neurodegenerative Diseases.
Nutritional prevention of cognitive decline and dementia.
Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
The sources and mechanisms of bioactive ingredients in coffee.
Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Green tea effects on cognition, mood and human brain function: A systematic review.
Effects of caffeine on the preterm brain: An observational study.
Reduced Stress and Improved Sleep Quality Caused by Green Tea Are Associated with a Reduced Caffeine Content.
Neuroprotective Effects and Mechanisms of Tea Bioactive Components in Neurodegenerative Diseases.
Health Benefits of Bioactive Compounds from the Genus Ilex, a Source of Traditional Caffeinated Beverages.
Coffee and Depression: A Short Review of Literature.
Therapeutic Opportunities for Caffeine and A2A Receptor Antagonists in Retinal Diseases.
Neuroprotection for premature infants?: another perspective on caffeine.
Association of Tea Consumption with Risk of Alzheimer's Disease and Anti-Beta-Amyloid Effects of Tea.
Caffeine and uric acid mediate glutathione synthesis for neuroprotection.
Stress-Reducing Function of Matcha Green Tea in Animal Experiments and Clinical Trials.
Exploring cocoa properties: is theobromine a cognitive modulator?
Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson`s Disease.
The science of tea's mood-altering magic.
Green tea (Camellia sinensis) and l-theanine: Medicinal values and beneficial applications in humans-A comprehensive review.
Caffeine as a psychomotor stimulant: mechanism of action.
Caffeine May Abrogate LPS-Induced Oxidative Stress and Neuroinflammation by Regulating Nrf2/TLR4 in Adult Mouse Brains.
Caffeine citrate: when and for how long. A literature review.
Vision Assessments and Interventions for Infants 0-2 Years at High Risk for Cerebral Palsy: A Systematic Review.
Disease-modifying strategies for Parkinson's disease.
Glutamate-mediated effects of caffeine and interferon-gamma on mercury-induced toxicity.
Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases.
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening.
An intervention study on the effect of matcha tea, in drink and snack bar formats, on mood and cognitive performance.
Caffeine increases cerebral cortical activity in preterm infants.
Natural or Plant Products for the Treatment of Neurological Disorders: Current Knowledge.
Caffeine prevents human prion protein-mediated neurotoxicity through the induction of autophagy.
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
Quercetin, not caffeine, is a major neuroprotective component in coffee.
Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma.
Caffeine-free hawk tea lowers cholesterol by reducing free cholesterol uptake and the production of very-low-density lipoprotein.
The role and regulation of adenosine in the central nervous system.
Single Dose Caffeine Protects the Neonatal Mouse Brain against Hypoxia Ischemia.
Caffeine and Parkinson's disease: are we getting our fix on risk-modifying gene-environment interactions?
Does caffeine intake protect from Alzheimer's disease?
Caffeine: neuroprotective functions in cognition and Alzheimer's disease.
Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.
Comparative proteomics reveals concordant and discordant biochemical effects of caffeine versus epigallocatechin-3-gallate in human endothelial cells.
Pathophysiological roles for purines: adenosine, caffeine and urate.
Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks.
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.
Pilot dose-escalation study of caffeine plus ethanol (caffeinol) in acute ischemic stroke.
Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons.
Caffeine as a neuroprotective adenosine receptor antagonist.
Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Synthesis and Characterization of a New Bivalent Ligand Combining Caffeine and Docosahexaenoic Acid.
Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.
The neuroprotective effects of caffeine: a prospective population study (the Three City Study).
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease.
Lost in translation: taking neuroprotection from animal models to clinical trials.
(-)-Epigallocatechin-3-O-gallate (EGCG) attenuates the hemodynamics stimulated by caffeine through decrease of catecholamines release.
Psychological effects of dietary components of tea: caffeine and L-theanine.
Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.
Association between caffeine intake and risk of Parkinson's disease among fast and slow metabolizers.
Neuroprotective, antiapoptotic and antioxidant effects of l-carnitine against caffeine-induced neurotoxicity in SH-SY5Y neuroblastoma cell line.
Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies.
An Insight into the Therapeutic Potential of Major Coffee Components.
Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine.
Treatment with A(2A) receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage.
Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice.
Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans.
Therapeutic advances in narcolepsy.
Caffeinated clues and the promise of adenosine A(2A) antagonists in PD.
Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss.
Evaluation of the efficacy of caffeine cessation, nortriptyline, and topiramate therapy in vestibular migraine and complex dizziness of unknown etiology.
Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.
A prospective study of tea and coffee intake and risk of glioma.
Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection.
Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury.
Physiological effects of caffeine, epigallocatechin-3-gallate, and exercise in overweight and obese women.
CATECHINS PROFILE, CAFFEINE CONTENT AND ANTIOXIDANT ACTIVITY OF CAMELLIA SINENSIS TEAS COMMERCIALIZED IN ROMANIA.
Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.
Amyloid Aggregation of Insulin: An Interaction Study of Green Tea Constituents.
Impact of common treatments given in the perinatal period on the developing brain.
Effects of the Green Tea Polyphenol Epigallocatechin-3-Gallate on Glioma: A Critical Evaluation of the Literature.
Plant alkaloids as drug leads for Alzheimer's disease.
Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men.
Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects.
Effects of co-administration of tea epigallocatechin-3-gallate (EGCG) and caffeine on absorption and metabolism of EGCG in humans.
Neuroadaptations in adenosine receptor signaling following long-term ethanol exposure and withdrawal.
Influence of short-term consumption of the caffeine-free, epigallocatechin-3-gallate supplement, Teavigo, on resting metabolism and the thermic effect of feeding.
Tea and cancer prevention: studies in animals and humans.
Idiopathic REM sleep behavior disorder and neurodegenerative risk: To tell or not to tell to the patient? How to minimize the risk?
Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease.
Selective inhibition of human acetylcholinesterase by xanthine derivatives: in vitro inhibition and molecular modeling investigations.
Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.
Comparison of white tea, green tea, epigallocatechin-3-gallate, and caffeine as inhibitors of PhIP-induced colonic aberrant crypts.
Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease.
An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's disease.
Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.
A2A receptors in neuroprotection of dopaminergic neurons.
Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results.
Neuroprotective effects of white tea against oxidative stress-induced toxicity in striatal cells.
Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.